Union Pharmaceuticals
Products
undefined
Treatment of mild to moderate Alzheimer's syndrome. It is the second drug approv₹ed by FDA for Alzheimer's disease in the United States. Its treatment reaches the target dose and has low toxic and side effects. It has been widely recognized by our medical community, and good tolerance is its£ biggest advantage. In October 1999, Donepezil was launched in Chin a under the trade name "Aricept", which is the main chemical drug against A₩lzheimer's disease. At present, CFDA has approved a number of domestic enterβprises to produce donepezil preparations, the main dosage forms are tabletsφ, capsules, dispersive tablets, oral disintegrating tablets.
隐藏域元素占位
undefined
It is a nucleotide analogue developed by Bioenvision$ and manufactured by Genzyme. On December 29, 2004, it was approved by FDA foβr the treatment of refractory or relapsed acute lymphoblastic leukemia (ALL) in c↑hildren.
隐藏域元素占位
undefined
The non-steroidal anti-inflammatory drug ketoprofen is o"ne of the most important products for the treatment of arthritis. It is well tolerated ≤and has a low incidence of side effects
隐藏域元素占位
undefined
Pranlukast, developed by Ono, is one of the three major leukotriene receptor antagonists. I≤n clinical application, it has good therapeutic effect on atopic asthma and other types of bronchial asthma, and the market prospect is huge. In the major categor₽y of asthma drugs, leukotriene receptor antagonists have the fastest growing market ↕share.
隐藏域元素占位
undefined
Chenglian Pharmaceutical is an innovative high-tech pharm•aceutical enterprise that is market-oriented and realizes ↓industrial development through R&D innovation and technology transformation.₩
隐藏域元素占位
undefined
undefined
Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enterprise that i®s market-oriented and realizes industrial development through R&D innovation a↓nd technology transformation.
隐藏域元素占位
undefined
1-O-Acetyl-2,3,5-Tri-O-Benzoyl-β-D-Ribofuranose
Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enterprise that∏ is market-oriented and realizes industrial development through R&D in♣novation and technology transformation.
隐藏域元素占位
undefined
English name Apixaban Trade name ELIQUIS, tablet: Apixaban (Eliquis, Bristol-Myers Squibb/Pfizer✘), a direct oral factor Xa inhibitor, was approved for use in the 27 EU member states. The world&#x¶27;s first drug approved to prevent venous thromboembolism (VTE) in adult patients≤ undergoing elective hip or knee replacement. From June 2019 to June 2020, the annual sales of ap✘ixaban products overseas reached about $15.4 billion, ★with a year-on-year growth of nearly 32%, and the API con→sumption reached about 23,960 kg, with a year-on-year growth of about 28%. Compared with it↔s main competitor, Rivaroxaban, the drug's annual overseas sales are about $•4.5 billion higher.
隐藏域元素占位
undefined
Sitagliptin Phosphate Monohydrate
Sitagliptin phosphate is a dipeptidyl peptidase-4 (<DPP4) inhibitor developed by Merck. In October 2006, Sitagliptin phosphate Januviβa was approved by FDA as the first DPP4 inhibitor for the treatment of type ⅱ dia✘betes mellitus. The characteristics of this drug are that it can stimulate ∏insulin secretion while reducing hunger without causing weight gain. Hypoglycemia aαnd edema will not occur, and it is suitable for diabetic patients with poor blood glucose βcontrol and frequent hypoglycemia.
隐藏域元素占位
News
undefined
Follow WeChat
Anhui Union Pharmaceuticals Technology Co., Ltd.
Service line:
+86-21-54285906
E-mail：2880705932@qq.com
Add：4th Floor, Building B3, Creative Industry Park, Hefei, Anhui P★. R. China.
Copyright © 2022 Anhui Union Pharmaceuticals Technology Co., Ltd.